US 8,618,103 B2Granted

Inhibitors of JAK

AssigneeHoffmann-La Roche Inc.

InventorsJavier de Vicente Fidalgo, Johannes Cornelius Hermann, Remy Lemoine, Hongju Li, Allen John Lovey, Eric Brian Sjogren, Michael Soth

Life of this patent

Estimating the term…

Abstract

The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R′, X, X′, Y, Z1, Z2, and Z3 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

Claims27

Dependent claims

A compound of Formula I

wherein:
R is lower alkyl, lower haloalkyl, lower alkoxy, hydroxy lower alkyl, hydroxy, or halogen;
n is 0 or 1;
Z1 is NH;
Z2 is CH;
Z3 is CR1;
R1 is H, lower alkyl, cycloalkyl, cyano, cyano lower alkyl, or halogen;
X is CH, CR′, or N;
X′ is CH, CR′, or N;
r is 0 or 1;
Y is CH, CR′, or N;
R′ is R′a or R′b;
R′a is halogen or cyano;
R′b is lower alkyl, cycloalkyl, heterocycloalkyl, OR″, SR″, S(═O)2R″, or NR″R″, optionally substituted with one or more R′c;
R′c is hydroxy, halogen, oxo, cyano, lower alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, carboxy lower alkyl, amino, amino carboxy lower alkyl, lower alkyl amino, lower dialkyl amino, lower haloalkyl, or lower alkoxy;
m is 0 or 1;
R″ is H, lower alkyl, hydroxy lower alkyl, heteroaryl, or lower alkoxy;
Q is H, S(═O)2Q1, C(═O)Q2, C(═O)OQ3, or Q4;
Q1 is lower alkyl, cycloalkyl lower alkyl, lower alkyl amino, lower dialkyl amino, or cycloalkyl, optionally substituted with one or more Q1′;
each Q1′ is independently halogen, lower alkyl, cyano, or lower alkoxy;
Q2 is lower alkyl, cycloalkyl lower alkyl, or cycloalkyl, optionally substituted with one or more Q2′;
each Q2′ is independently halogen, lower alkyl, cyano, or lower alkoxy;
Q3 is lower alkyl, cycloalkyl lower alkyl, or cycloalkyl, optionally substituted with one or more Q3′;
each Q3′ is independently halogen, lower alkyl, or lower alkoxy;
Q4 is lower alkyl, cycloalkyl lower alkyl, heterocycloalkyl, or cycloalkyl, optionally substituted with one or more Q4′;
each Q4′ is independently halogen, cyano, cyano lower alkyl, lower alkyl, or lower alkoxy;
p is 0, 1, or 2;
q is 1 or 2;
each represents a single bond or a double bond;
and
with the proviso that the bonds between Z1 and Z2 and Z2 and Z3 are not both double bonds and are not both single bonds;
or a pharmaceutically acceptable salt thereof.

29 more elements

A compound selected from the group consisting of:

((S)-1-Methanesulfonyl-piperidin-3-yl)-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
((R)-1-Methanesulfonyl-piperidin-3-yl)-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
1-{(R)-3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-pyrrolidin-1-yl}-ethanone;
(R)-3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-pyrrolidine-1-carboxylic acid methyl ester;
((R)-1-Methanesulfonyl-pyrrolidin-3-yl)-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
1-{(R)-3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidin-1-yl}-ethanone;
4-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidine-1-carboxylic acid methyl ester;
1-{4-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidin-1-yl}-ethanone;
1-{(S)-3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-pyrrolidin-1-yl}-ethanone;
(S)-3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-pyrrolidine-1-carboxylic acid methyl ester;
((S)-1-Methanesulfonyl-pyrrolidin-3-yl)-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
1-{3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-azepan-1-yl}-ethanone;
3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-azepane-1-carboxylic acid methyl ester;
(1-Methanesulfonyl-azepan-3-yl)-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[(R)-1-(Propane-2-sulfonyl)-piperidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
((R)-1-Ethanesulfonyl-pyrrolidin-3-yl)-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[(R)-1-(Propane-1-sulfonyl)-pyrrolidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[(R)-1-(Propane-2-sulfonyl)-pyrrolidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[(R)-1-(2-Methyl-propane-1-sulfonyl)-pyrrolidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
1-{(R)-3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-pyrrolidin-1-yl}-propan-1-one;
1-{(R)-3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-pyrrolidin-1-yl}-butan-1-one;
2-Methyl-1-{(R)-3-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-pyrrolidin-1-yl}-propan-1-one;
3-Methyl-1-{(R)-3-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-pyrrolidin-1-yl}-butan-1-one;
((3S,5S)-1-Methanesulfonyl-5-methyl-piperidin-3-yl)-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[(3S,5S)-5-Methyl-1-(propane-1-sulfonyl)-piperidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[(3S,5S)-5-Methyl-1-(2-methyl-propane-1-sulfonyl)-piperidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[(R)-1-(3-Methyl-butane-1-sulfonyl)-pyrrolidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[(3S,5S)-5-Methyl-1-(propane-2-sulfonyl)-piperidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[(S)-1-(2-Methyl-propane-1-sulfonyl)-piperidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
1-{3-[6-Methyl-3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidin-1-yl}-ethanone;
(1-Methanesulfonyl-piperidin-3-yl)-[6-methyl-3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[(S)-1-(2,2-Dimethyl-propane-1-sulfonyl)-piperidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-[(S)-1-(2,2,2-trifluoro-ethyl)-piperidin-3-yl]-amine;
(1-Ethanesulfonyl-piperidin-3-yl)-[6-methyl-3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
(1-Cyclopropylmethanesulfonyl-piperidin-3-yl)-[6-methyl-3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[1-(2,2-Dimethyl-propane-1-sulfonyl)-piperidin-3-yl]-[6-methyl-3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
(1-Methanesulfonyl-azepan-4-yl)-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
((S)-1-Cyclopropylmethanesulfonyl-piperidin-3-yl)-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
1-{3-[3-(7-Chloro-5H-pyrrolo[2,3-b]pyrazin-2-yl)-6-methyl-pyridin-2-ylamino]-piperidin-1-yl}-ethanone;
[3-(7-Chloro-5H-pyrrolo[2,3-b]pyrazin-2-yl)-6-methyl-pyridin-2-yl]-(1-cyclopropylmethanesulfonyl-piperidin-3-yl)-amine;
((S)-1-Methanesulfonyl-piperidin-3-yl)-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrazin-2-yl]-amine;
{(S)-3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidine-1-sulfonyl}-acetonitrile;
[(S)-1-(2-Methyl-propane-1-sulfonyl)-piperidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrazin-2-yl]-amine;
2-[2-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-pyridin-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carbonitrile;
((S)-1-Methanesulfonyl-piperidin-3-yl)-[3-(7-methyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[3-(7-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-((S)-1-methanesulfonyl-piperidin-3-yl)-amine;
[3-(7-Chloro-5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-((S)-1-methanesulfonyl-piperidin-3-yl)-amine;
(3R,4R)-1-(2-Methyl-propane-1-sulfonyl)-3-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidin-4-ol;
(3R,4R)-1-Methanesulfonyl-3-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidin-4-01;
(S)-3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidine-1-sulfonic acid dimethylamide;
(S)-3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidine-1-sulfonic acid tert-butylamide;
((S)-1-Methanesulfonyl-piperidin-3-yl)-[5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
[(S)-1-(2-Methyl-propane-1-sulfonyl)-piperidin-3-yl]-[5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
N4-[(S)-1-(2-Methyl-propane-1-sulfonyl)-piperidin-3-yl]-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidine-2,4-diamine;
N2,N2-Dimethyl-N-4-[(S)-1-(2-methyl-propane-1-sulfonyl)-piperidin-3-yl]-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidine-2,4-diamine;
[2-Methanesulfonyl-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-[(S)-1-(2-methyl-propane-1-sulfonyl)-piperidin-3-yl]-amine;
[(S)-1-(2-Methyl-propane-1-sulfonyl)-piperidin-3-yl]-[2-methylsulfanyl-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
[(S)-1-(2-Methyl-propane-1-sulfonyl)-piperidin-3-yl]-[2-morpholin-4-yl-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
((S)-1-Methanesulfonyl-piperidin-3-yl)-[2-methylsulfanyl-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
N4-((S)-1-Methanesulfonyl-piperidin-3-yl)-N2,N2-dimethyl-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidine-2,4-diamine;
N4-((S)-1-Methanesulfonyl-piperidin-3-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidine-2,4-diamine;
2-[2-Dimethylamino-4-((S)-1-methanesulfonyl-piperidin-3-ylamino)-pyrimidin-5-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carbonitrile;
[(S)-1-(3,3-Dimethyl-butane-1-sulfonyl)-piperidin-3-yl]-[2-methylsulfanyl-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
((S)-1-Methanesulfonyl-piperidin-3-yl)-[2-methoxy-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
[2-Chloro-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-((S)-1-methanesulfonyl-piperidin-3-yl)-amine;
((S)-1-Methanesulfonyl-piperidin-3-yl)-[2-(4-methyl-piperazin-1-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-2-ol;
[2-Ethoxy-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-((S)-1-methanesulfonyl-piperidin-3-yl)-amine;
2-[4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-2-ylamino]-ethanol;
N4-((S)-1-Methanesulfonyl-piperidin-3-yl)-N2-(2-methoxy-ethyl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidine-2,4-diamine;
((S)-1-Methanesulfonyl-piperidin-3-yl)-[2-morpholin-4-yl-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
3-{(S)-3-[2-Methylsulfanyl-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-ylamino]-piperidin-1-yl}-3-oxo-propionitrile;
1-[4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-2-ylamino]-2-methyl-propan-2-ol;
[2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-((S)-1-methanesulfonyl-piperidin-3-yl)-amine;
((S)-1-Methanesulfonyl-piperidin-3-yl)-[2-(4-methoxy-piperidin-1-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
N2-(2-Amino-ethyl)-N4-((S)-1-methanesulfonyl-piperidin-3-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidine-2,4-diamine;
2-{1-[4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-2-yl]-piperidin-4-yl}-acetamide;
(S)-2-[4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-2-ylamino]-butan-1-ol;
(R)-2-[4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-2-ylamino]-butan-1-ol;
N4-((S)-1-Methanesulfonyl-piperidin-3-yl)-N2-(1-methyl-piperidin-4-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidine-2,4-diamine;
[(S)-1-(3,3-Dimethyl-butane-1-sulfonyl)-piperidin-3-yl]-[2-(4-methyl-piperazin-1-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
[2-(4-Dimethylamino-piperidin-1-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-((S)-1-methanesulfonyl-piperidin-3-yl)-amine;
4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidine-2-carbonitrile;
(S)-1-[4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-2-yl]-pyrrolidin-3-ol;
(R)-1-[4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-2-yl]-pyrrolidin-3-ol;
1-[4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-2-yl]-azetidine-3-carbonitrile;
4-[4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-2-ylamino]-cyclohexanecarbonitrile;
((S)-1-Methanesulfonyl-piperidin-3-yl)-[2-(4-pyridin-2-yl-piperazin-1-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
{1-[4-((S)-1-Methanesulfonyl-piperidin-3-ylamino)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-2-yl]-piperidin-4-yl}-acetic acid;
N4-((S)-1-Methanesulfonyl-piperidin-3-yl)-N2-pyridin-4-yl-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidine-2,4-diamine;
N2-(2-Dimethylamino-ethyl)-N4-((S)-1-methanesulfonyl-piperidin-3-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidine-2,4-diamine;
[2-(4-Ethyl-piperazin-1-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-((S)-1-methanesulfonyl-piperidin-3-yl)-amine;
[2-((R)-3-Dimethylamino-pyrrolidin-1-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-((S)-1-methanesulfonyl-piperidin-3-yl)-amine;
[2-(4-Methyl-piperazin-1-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-[(S)-1-(2-methyl-propane-1-sulfonyl)-piperidin-3-yl]-amine;
[(3S,5S)-5-Methyl-1-(2-methyl-propane-1-sulfonyl)-piperidin-3-yl]-[2-(4-methyl-piperazin-1-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
{(3S,5S)-3-Methyl-5-[2-(4-methyl-piperazin-1-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-ylamino]-piperidine-1-sulfonyl}-acetonitrile;
((3S,5S)-1-Methanesulfonyl-5-methyl-piperidin-3-yl)-[2-(4-methyl-piperazin-1-yl)-5-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyrimidin-4-yl]-amine;
((3S,5S)-1-Methanesulfonyl-5-trifluoromethyl-piperidin-3-yl)-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
[(3S,5S)-1-(2-Methyl-propane-1-sulfonyl)-5-trifluoromethyl-piperidin-3-yl]-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-amine;
(3-{(S)-3-[3-(5H-Pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidin-1-yl}-oxetan-3-yl)-acetonitrile;
(3-{(3S,5S)-3-Methyl-5-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidin-1-yl}-oxetan-3-yl)-acetonitrile;
{(3S,5S)-3-Methyl-5-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidine-1-sulfonyl}-acetonitrile;
and
4,4,4-Trifluoro-3-{(S)-3-[3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-ylamino]-piperidin-1-yl}-butyronitrile.

101 more elements

Dependencies are inferred from the claim text.

Facts

Application: 12/878,048Filed 9 Sep 2010 · us provisional application
Priority: 10 Sep 2009
Published: US 2011/0059118 A110 Mar 2011
Granted: 31 Dec 2013
Term ends: Not estimatedThe source records don’t support an estimate.

Classification20 codes

C07D 487/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
A61P 5/14
Drugs for disorders of the endocrine system: of the thyroid hormones, e.g. T3, T4

Family

Application61/241,095Us provisional application · filed 10 Sep 2009
Application61/367,639Us provisional application · filed 26 Jul 2010
US 2011/0059118 A1Pre-grant publication · published 10 Mar 2011
US 8,618,103 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

Facts

Application

12/878,048Filed 9 Sep 2010 · us provisional application

Priority

10 Sep 2009

Published

US 2011/0059118 A110 Mar 2011

Granted

31 Dec 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

C07D 487/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
A61P 5/14
Drugs for disorders of the endocrine system: of the thyroid hormones, e.g. T3, T4